Collaboration to develop MS myelin regenerative compounds
Posted: Thu Feb 09, 2012 3:59 am
The Myelin Repair Foundation (MRF) and ENDECE Neural, LLC have formed a partnership to expedite the advancement of myelin regeneration drug candidates for Multiple Sclerosis (MS) patients through pre-clinical studies and into Phase I clinical studies.
Through this unique collaboration, the newly launched MRF Translational Medicine Center will assess the myelin regenerating capabilities of proprietary small molecule compounds from ENDECE Neural in novel MRF Multiple Sclerosis models for their effectiveness in reversing myelin damage.
These ENDECE Neural compounds will be evaluated at the MRF Translational Medicine Center, which is dedicated to the acceleration of the drug discovery and development process for new MS treatments. This laboratory facility offers a rigorous, industry-leading translational medicine platform, led by MRF personnel with over four decades of extensive biopharma experience moving therapeutic compounds into clinical trials. The goal of the MRF Translational Medicine Center is to advance potential myelin repair treatment targets toward commercialization to benefit MS patients.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1845